Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2019

01-08-2019 | Mesothelioma | Review Article

The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment

Authors: Vasiliki Galani, Anna Varouktsi, Stamatis S. Papadatos, Antigoni Mitselou, Ioannis Sainis, Stavros Constantopoulos, Yotanna Dalavanga

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2019

Login to get access

Abstract

Malignant mesothelioma (MM) is a highly aggressive tumor that is strongly related to asbestos fiber exposure. The tumorigenesis procedure in MM is complex, and many pathogenetic mechanisms including chronic inflammation, deregulation of cell death, and the genomic copy-number losses and gains may contribute to carcinogenesis. MM cells are resistant to TRAIL-mediated apoptosis due to defects in extrinsic apoptotic pathway. CAPS, a regulator of cell cycle and death, may contribute to the MM development as well. BAP1 is the most frequently inactivated gene in MPM; BAP1 deficiency triggers malignant transformation via disruption of DNA repair, transcription regulation, cell metabolism, apoptosis, and ferroptosis. In addition, bcl-2 family proteins as well as abnormal activation of PI3 K/Akt/mTOR pathway and deregulation of the Wnt signaling pathway may result in MM tumorigenesis. Finally, the Hippo pathway plays a critical role in MPM development. Mutations of NF2 and LATS lead to YAP activation in MPM. Thus, inhibition of YAP activity by YAP inhibitors could be a potentially promising treatment option for MM. In conclusion, extensive genetic alterations exist in mesotheliomas associated with the signaling of apoptotic HM cells death. The comprehension of these pathways may contribute to enhancing survival via developing new effective therapeutic strategies.
Literature
1.
Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT et al (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 133(8):1317–1331PubMed
2.
Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA et al (2012) Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 227(1):44–58CrossRefPubMedPubMedCentral
3.
Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL (2018) Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med 142(6):753–760CrossRefPubMed
4.
Galani V, Constantopoulos S, Manda-Stachouli C, Frangou-Lazaridis M, Mavridis A, Vassiliou M et al (2002) Additional proteins in BAL fluid of Metsovites environmentally exposed to asbestos: more evidence of “protection” against neoplasia? Chest 121(1):273–278CrossRefPubMed
5.
Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C et al (2010) Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 107(28):12611–12616CrossRefPubMedPubMedCentral
6.
Carbone M, Yang H (2012) Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 18:598–604CrossRefPubMed
7.
8.
Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M (2013) Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 229:176–185CrossRefPubMed
9.
10.
Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ (2011) Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 117:5234–5244CrossRefPubMed
11.
Archimandriti DT, Dalavanga YA, Cianti R, Bianchi L, Manda-Stachouli C, Armini A et al (2009) Proteome analysis of bronchoalveolar lavage in individuals from Metsovo, nonoccupationally exposed to asbestos. J Proteome Res 8(2):860–869CrossRefPubMed
12.
Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I et al (2018) A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol 36:3485–3494CrossRefPubMedCentral
13.
Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN et al (2018) Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol 36(28):2863–2871CrossRefPubMedPubMedCentral
14.
Bueno R, Stawiski EW, Goldstein LD et al (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48(4):407–416CrossRefPubMed
15.
Huang SXL, Jaurand MC, Kamp DW, Whysner J, Hei TK (2011) Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B Crit Rev 14(1–4):179–245CrossRefPubMedPubMedCentral
16.
Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Nakai T et al (2014) Comparison of genomic abnormality in malignant mesothelioma by the site of origin. J Clin Pathol 67(12):1038–1043CrossRefPubMed
17.
Borczuk AC, Pei J, Taub RN, Levy B, Nahum O, Chen J et al (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17(3):328–335CrossRefPubMedPubMedCentral
18.
Galani V, Tatsaki E, Bai M, Kitsoulis P, Lekka M, Nakos G et al (2010) The role of apoptosis in the pathophysiology of Acute Respiratory Distress Syndrome (ARDS): an up-to-date cell-specific review. Pathol Res Pract 206:145–150CrossRefPubMed
19.
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P et al (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3):486–541CrossRefPubMedPubMedCentral
20.
Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2(4):277–288CrossRefPubMed
21.
Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA (2007) Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 6:66CrossRefPubMedPubMedCentral
22.
Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z et al (2005) A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 33(6):541–548CrossRefPubMedPubMedCentral
23.
Rippo MR, Moretti S, Vescovi S, Tomasetti M, Orecchia S, Amici G et al (2004) FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 23(47):7753–7760CrossRefPubMed
24.
Liu W, Bodle E, Chen JY, Gao M, Rosen GD, Broaddus VC (2001) Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 25(1):111–118CrossRefPubMed
25.
Tomasetti M, Rippo MR, Alleva R, Moretti S, Andera L, Neuzil J et al (2004) Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. Br J Cancer 90(8):1644–1653CrossRefPubMedPubMedCentral
26.
Abayasiriwardana KS, Barbone D, Kim KU, Vivo C, Lee KK, Dansen TB et al (2007) Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther 6(10):2766–2776CrossRefPubMed
27.
Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W et al (2009) Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther 8(24):2406–2416CrossRefPubMed
28.
Heintz NH, Janssen-Heininger YM, Mossman BT (2010) Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 42(2):133–139CrossRefPubMedPubMedCentral
29.
Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z et al (2006) TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103(27):10397–10402CrossRefPubMedPubMedCentral
30.
Raphaël M, Lehen’kyi V, Vandenberghe M, Beck B, Khalimonchyk S, Abeele F et al (2014) TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. Proc Natl Acad Sci USA 111(37):E3870–E3879CrossRefPubMedPubMedCentral
31.
Li F, Zhu D, Yang Y, Wu K, Zhao S (2017) Overexpression of calcyphosine is associated with poor prognosis in esophageal squamous cell carcinoma. Oncol Lett 14(5):6231–6237PubMedPubMedCentral
32.
Ramos-Nino ME, Timblin CR, Mossman BT (2002) Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 62(21):6065–6069PubMed
33.
Manning CB, Sabo-Attwood T, Robledo RF, Macpherson MB, Rincon M, Vacek P (2008) Targeting the MEK1 cascade in lung epithelium inhibits proliferation and fibrogenesis by asbestos. Am J Respir Cell Mol Biol 38:618–626CrossRefPubMedPubMedCentral
34.
Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ et al (2011) ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer 129(5):1075–1086CrossRefPubMedPubMedCentral
35.
Masuelli L, Benvenuto M, Stefano ED, Mattera R, Fantini M, Feudis GD et al (2017) Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line. Oncotarget 8(21):34405–34422CrossRefPubMedPubMedCentral
36.
Li Q, Kawamura K, Yamanaka M, Okamoto S, Yang S, Yamauchi S et al (2012) Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesotheliomaand enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther 19(3):218–228CrossRefPubMed
37.
Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Pääkkö P (1999) Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 5:3508–3515PubMed
38.
Mohiuddin I, Cao X, Fang B, Nishizaki M, Smythe WR (2001) Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther 8:547–554CrossRefPubMed
39.
Smythe WR, Mohuiddin I, Ozveran M, Cao XX (2002) Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 123:1191–1198CrossRefPubMed
40.
Cao X, Rodarte C, Zhang L, Morgan CD, Littlejohn J, Smythe WR (2007) Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol Ther 6(2):246–252CrossRefPubMed
41.
Littlejohn JE, Cao X, Miller SD, Ozvaran MK, Jupiter D, Zhang L et al (2008) Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer 123(1):202–208CrossRefPubMed
42.
Varin E, Denoyelle C, Brotin E, Meryet-Figuière M, Giffard F, Abeilard E et al (2010) Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 31(6):984–993CrossRefPubMed
43.
Daubriac J, Fleury-Feith J, Kheuang L, Galipon J, Saint-Albin A, Renier A et al (2009) Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. Cell Death Differ 16(8):1146–1155CrossRefPubMed
44.
Sugarbaker DJ, Richards WG, Gordon GJ, Dong L, De Rienzo A, Maulik G et al (2008) Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci USA 105(9):3521–3526CrossRefPubMedPubMedCentral
45.
46.
Galani V, Kastamoulas M, Varouktsi A, Lampri E, Mitselou A, Arvanitis DL (2017) IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review. Clin Exp Med 17(3):281–289CrossRefPubMed
47.
Galani V, Papadatos SS, Alexiou G, Galani A, Kyritsis AP (2017) In vitro and in vivo preclinical effects of type I IFNs on gliomas. J Interferon Cytokine Res 37(4):139–146CrossRefPubMed
48.
Hong TM, Yang PC, Peck K, Chen JJ, Yang SC, Chen YC et al (2000) Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am J Respir Cell Mol Biol 23(3):355–363CrossRefPubMed
49.
Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S et al (2014) Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. Br J Cancer 110(10):2479–2488CrossRefPubMedPubMedCentral
50.
Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A et al (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24(40):6080–6089CrossRefPubMed
51.
Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K et al (2009) Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2(2):181–188PubMed
52.
Pinton G, Manente AG, Angeli G, Mutti L, Moro L (2012) Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS ONE 7(5):e36856CrossRefPubMedPubMedCentral
53.
Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC (2008) Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 283(19):13021–13330CrossRefPubMedPubMedCentral
54.
Wilson SM, Barbone D, Yang TM, Jablons DM, Bueno R, Sugarbaker DJ et al (2008) mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol 39(5):576–583CrossRefPubMedPubMedCentral
55.
Vivo C, Liu V, Broaddus VC (2003) c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 278(28):25461–25467CrossRefPubMed
56.
Holley SL, Fryer AA, Haycock JW, Grubb SE, Strange RC, Hoban PR (2007) Differential effects of glutathione S-transferase pi (GSTP1) haplotypes on cell proliferation and apoptosis. Carcinogenesis 28(11):2268–2273CrossRefPubMed
57.
Kastamoulas M, Chondrogiannis G, Kanavaros P, Vartholomatos G, Bai M, Briasoulis E et al (2013) Cytokine effects on cell survival and death of A549 lung carcinoma cells. Cytokine 61(3):816–825CrossRefPubMed
58.
59.
Mazieres J, You L, He B, Xu Z, Twogood S, Lee AY et al (2005) Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int J Cancer 117(2):326–332CrossRefPubMed
60.
Kashiwakura Y, Ochiai K, Watanabe M, Abarzua F, Sakaguchi M, Takaoka M et al (2008) Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res 68(20):8333–8341CrossRefPubMed
61.
62.
Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P et al (2018) BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 20:1181–1192CrossRefPubMedPubMedCentral
63.
Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L et al (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668–672CrossRefPubMedPubMedCentral
64.
Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022–1025CrossRefPubMedPubMedCentral
65.
Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H et al (2015) Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36(1):76–81CrossRefPubMed
66.
67.
Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H et al (2015) High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 10:565–576CrossRefPubMedPubMedCentral
68.
Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T et al (2016) High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc Natl Acad Sci USA 113:13432–13437CrossRefPubMedPubMedCentral
69.
Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M et al (2017) BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature 546:549–553CrossRefPubMedPubMedCentral
70.
71.
Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M et al (2019) BAP1 Status Determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. Int J Mol Sci 20(2):E429CrossRefPubMed
72.
Napolitano A, Pellegrini L, Dey A, Larson D, Tanji M, Flores EG et al (2016) Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35(15):1996–2002CrossRefPubMed
73.
Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E et al (2014) Germline mutation of Bap1 accelerates development of asbestos-induced malignantmesothelioma. Cancer Res 74(16):4388–4397CrossRefPubMedPubMedCentral
74.
Kadariya Y, Cheung M, Xu J, Pei J, Sementino E, Menges CW et al (2016) Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res 76(9):2836–2844CrossRefPubMedPubMedCentral
75.
Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M et al (2016) Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res 76(2):206–215CrossRefPubMed
76.
Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S et al (2017) BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J Thorac Oncol 12(4):724–733CrossRefPubMed
77.
Carbone M, Shimizu D, Napolitano A, Tanji M, Pass HI, Yang H et al (2016) Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. Oncotarget 7(37):59314–59321CrossRefPubMedPubMedCentral
78.
Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L et al (2011) Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 37(7):543–558CrossRefPubMed
79.
80.
Gyrd-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer. Nat Rev Cancer 10(8):561–574CrossRefPubMed
81.
Sun X, Gulyás M, Hjerpe A, Dobra K (2006) Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett 232(2):161–169CrossRefPubMed
82.
Borczuk AC, Cappellini GC, Kim HK, Hesdorffer M, Taub RN, Powell CA (2007) Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 26(4):610–617CrossRefPubMed
83.
Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL et al (2008) Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61(4):549–558CrossRefPubMed
84.
Wang Y, Rishi AK, Puliyappadamba VT, Sharma S, Yang H, Tarca A et al (2010) Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol 66(3):455–466CrossRefPubMed
85.
Chondrogiannis G, Kastamoulas M, Kanavaros P, Vartholomatos G, Bai M, Baltogiannis D et al (2014) Cytokine effects on cell death and major signaling pathways in LNCaP prostate carcinoma cells. B Biomed Res Int 2014:536049PubMed
86.
Jin L, Amatya VJ, Takeshima Y, Shrestha L, Kushitani K, Inai K (2010) Evaluation of apoptosis and immunohistochemical expression of the apoptosis-related proteins in mesothelioma. Hiroshima J Med Sci 59(2):27–33PubMed
87.
Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K et al (2002) Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1(9):687–694PubMed
88.
Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M et al (2007) Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 29(6):453–466PubMedPubMedCentral
89.
90.
91.
92.
Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B et al (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854–10858CrossRefPubMedPubMedCentral
93.
Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF et al (1995) Neurofibromatosis Type-2 (Nf2) gene is somatically mutated in mesothelioma but not in lung-cancer. Cancer Res 55:1227–1231PubMed
94.
Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T et al (2011) LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71:873–883CrossRefPubMed
95.
Miyanaga A, Masuda M, Tsuta K, Kawasaki K, Nakamura Y, Sakuma T et al (2015) Hippo pathway gene mutations in malignant mesothelioma revealed by RNA and targeted exon sequencing. J Thorac Oncol 10:844–851CrossRefPubMed
96.
Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q et al (2014) Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med 6(237):237ra68CrossRefPubMedPubMedCentral
97.
Woodard GA, Yang YL, You L, Jablons DM (2017) Drug development against the hippo pathway in mesothelioma. Transl Lung Cancer Res 6(3):335–342CrossRefPubMedPubMedCentral
98.
Tranchant R, Quetel L, Montagne F, De Wolf J, Meiller C, De Koning L et al (2018) Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma. Lung Cancer 126:15–24CrossRefPubMed
99.
Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L et al (2017) Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clin Cancer Res 23(12):3191–3202CrossRefPubMed
100.
Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH et al (2017) HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget 8(14):22649–22661CrossRefPubMedPubMedCentral
101.
Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I et al (2012) Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Can Res 72(13):3290–3301CrossRef
102.
Edwards JC, Swinson DE, Jones JL, Waller DA, O’Byrne KJ (2006) EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54:399–407CrossRefPubMed
103.
Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J et al (2003) Gene expression profiling of malignant mesothelioma. Clin Cancer Res 9(8):3080–3097PubMed
Metadata
Title
The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment
Authors
Vasiliki Galani
Anna Varouktsi
Stamatis S. Papadatos
Antigoni Mitselou
Ioannis Sainis
Stavros Constantopoulos
Yotanna Dalavanga
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Keyword
Mesothelioma
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-019-03878-3

Other articles of this Issue 2/2019

Cancer Chemotherapy and Pharmacology 2/2019 Go to the issue

Original Article

SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4

Original Article

Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors

Original Article

Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer

Review Article

Cancer immunotherapy: the art of targeting the tumor immune microenvironment

Original Article

The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors

Short Communication

An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits